T cells are crucial for immune functions to maintain health and prevent disease. T cell
development occurs in a stepwise process in the thymus and mainly generates CD4+ and …

Antibody therapeutics are a large and rapidly expanding drug class providing major health
benefits. We provide a snapshot of current antibody therapeutics including their formats …

T-cell-engaging bispecific antibodies (BsAbs) simultaneously bind to antigens on tumour
cells and CD3 subunits on T cells. This simultaneous binding results in the recruitment of T …

Several current immunotherapy approaches target private neoantigens derived from
mutations that are unique to individual patients' tumors. However, immunotherapeutic …

During persistent antigen stimulation, such as in chronic infections and cancer, CD8 T cells
differentiate into a hypofunctional programmed death protein 1–positive (PD-1+) exhausted …

Bispecific antibodies (bsAbs) enable novel mechanisms of action and/or therapeutic
applications that cannot be achieved using conventional IgG-based antibodies …

The discovery of both cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and
programmed cell death protein 1 (PD1) as negative regulators of antitumour immunity led to …

The clinical development of 4–1BB agonists for cancer immunotherapy has raised
substantial interest during the past decade. The first generation of 4–1BB agonistic …

Bispecific antibodies (bsAb) that target two independent epitopes or antigens have been
extensively explored in translational and clinical studies since they were first developed in …

Although many patients with diffuse large B cell lymphoma (DLBCL) may achieve a
complete response to frontline chemoimmunotherapy, patients with relapsed/refractory …